Informations générales (source: ClinicalTrials.gov)
Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells (ANOPEC 3)
Interventional
N/A
Centre Hospitalier Universitaire de Besancon (Voir sur ClinicalTrials)
novembre 2013
novembre 2018
29 juin 2024
The study aims to investigate the existence of a reliable correlation between the
progression of aortic diameters and blood levels of circulant endothelial progenitor
cells CD34+ in patients with not surgical aortic aneurysms.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHRU de Besançon - 25000 - Besançon - France | Andréa PERROTTI, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Patients aged 18 or more.
2. Patients diagnosed with a thoracic or abdominal aortic aneurysm with no indication
for surgical treatment (diameters > 30 mm but < 50 mm).
3. Patients accepting to sign a specific informed consent.
1. Patients aged 18 or more.
2. Patients diagnosed with a thoracic or abdominal aortic aneurysm with no indication
for surgical treatment (diameters > 30 mm but < 50 mm).
3. Patients accepting to sign a specific informed consent.
1. Unstable coronary artery disease.
2. Congenital heart disease.
3. Any evolving infectious syndrome or viral infection (HIV, HBV or HCV).
4. Any chronic inflammatory or autoimmune disease.
5. Prior administration of G-CSF; EPO; GM-CSF.
6. Liver failure.
7. Prior oncologic disease or ongoing cancer with a life expectancy < 1 year.
8. Dementia.
9. Pregnancy.
10. Patients aged < 18.